MNK inhibitors and methods related thereto

1. A method for treating a Mnk dependent condition in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of at least one compound according to Formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof:

wherein:

W 1 and W 2 are independently O, S or N—OR′, where R′ is lower alkyl;

Y is —N(R 5 )—, —O—,—S—, —C(O)—, —S═O, —S(O) 2 —, or —CHR 9 —;

R 1 is hydrogen, lower alkyl, cycloalkyl or heterocyclyl wherein any lower alkyl, cycloalkyl or heterocyclyl is optionally substituted with 1, 2 or 3 J groups;

n is 1, 2 or 3;

R 2 and R 3 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, araalkylene, heteroaryl, heteroarylalkylene, cycloalkyl, cycloalkylalkylene, heterocyclyl, or heterocyclylalkylene, wherein any alkyl, aryl, araalkylene, heteroaryl, heteroarylalkylene, cycloalkyl, cycloalkylalkylene, heterocyclyl, or heterocyclylalkylene, is optionally substituted with 1, 2 or 3 J groups;

or R 2 and R 3 taken together with the carbon atom to which they are attached form a cycloalkyl or heterocyclyl, wherein any cycloalkyl or heterocyclyl is optionally substituted with 1, 2 or 3 J groups;

R 4a and R 4b are each independently hydrogen, halogen, hydroxyl, thiol, hydroxyalkylene, cyano, alkyl, alkoxy, acyl, thioalkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclyl;

R 5 is hydrogen, cyano, or lower alkyl;

or R 5 and R 8 taken together with the atoms to which they are attached form a fused heterocyclyl optionally substituted with 1, 2 or 3 J groups;

R 6 , R 7 and R 8 are each independently hydrogen, hydroxy, halogen, cyano, amino, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkylene, cycloalkylalkenylene, alkylaminyl, alkylcarbonylaminyl, cycloalkylcarbonylaminyl, cycloalkylaminyl, heterocyclylaminyl, heteroaryl, or heterocyclyl, and wherein any amino, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkylene, cycloalkylalkenylene, amino, alkylaminyl, alkylcarbonylaminyl, cycloalkylcarbonylaminyl, cycloalkylaminyl, heterocyclylaminyl, heteroaryl, or heterocyclyl is optionally substituted with 1, 2 or 3 J groups;

or R 7 and R 8 taken together with the atoms to which they are attached form a fused heterocyclyl or heteroaryl optionally substituted with 1, 2 or 3 J groups;

J is —SH, —SR 9 , —S(O)R 9 , —S(O) 2 R 9 , —S(O)NH 2 , —S(O)NR 9 R 9 , —NH 2 , —NR 9 R 9 , —COOH, —C(O)OR 9 , —C(O)R 9 , —C(O)—NH 2 , —C(O)—NR 9 R 9 , hydroxy, cyano, halogen, acetyl, alkyl, lower alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, thioalkyl, cyanoalkylene, alkylaminyl, NH 2 —C(O)-alkylene , NR 9 R 9 —C(O)-alkylene, —CHR 9 —C(O)-lower alkyl, —C(O)-lower alkyl, alkylcarbonylaminyl, cycloalkyl, cycloalkylalkylene, cycloalkylalkenylene, cycloalkylcarbonylaminyl, cycloalkylaminyl, —CHR 9 —C(O)-cycloalkyl, —C(O)-cycloalkyl, —CHR 9 —C(O)-aryl, —CHR 9 -aryl, —C(O)-aryl, —CHR 9 —C(O)-heterocycloalkyl, —C(O)-heterocycloalkyl, heterocyclylaminyl, or heterocyclyl; or any two J groups bound to the same carbon or hetero atom may be taken together to form oxo; and

R 9 is hydrogen, lower alkyl or —OH;

wherein the Mnk dependent condition is cancer or inflammation.

2. The method of claim 1 wherein n is 1 , Y is —N(R 5 )—, and W 1 and W 2 are O.

3. The method of claim 1 wherein R 2 and R 3 are each independently hydrogen , methyl, ethenylene, propynylene, 2-methyl-1-propenylene, benzyl, fluorobenzyl, chlorobenzyl, cyclopentyl, cyclohexyl, difluorocyclohexyl, iso-propyl, trifluoromethyl, 1,1,1-trifluoroethylene, thiophene, thiazole, methylenenitrile, chlorophenyl, fluorophenyl, fluorochlorophenyl, difluorophenyl, pyridine, methylpyridine, chloropyridine, N-methylaminomethylene, aminomethylene, 1-aminoethylene, t-butyl, methylaminomethylene, propyl, 1-hydroxyethylene, or 1,1-difluoroethylene.

4. The method of claim 1 wherein R 2 and R 3 together with the carbon atom to which they are attached forms a heterocyclyl ring that is optionally substituted with 1, 2 or 3 J groups selected from the group consisting of halogen, —CN, N-methyl amino, methyl, difluoroethylene, and methylenenitrile.

5. The method of claim 4 wherein the heterocyclyl ring is piperidine.

6. The method of claim 1 wherein R 4a and R 4b are each independently hydrogen, halogen, or alkyl.

7. The method of claim 1 wherein R 5 is hydrogen.

8. The method of claim 1 wherein R 6 and R 8 are hydrogen and R 7 is amino, cycloalkylcarbonylaminyl, heterocyclylaminyl, or cycloalkylalkylene.

9. The method of claim 1 wherein the compound or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof according to claim 1 selected from the group consisting of:

10. The method of claim 1 wherein the pharmaceutically acceptable salt of the Formula I compound is an organic or inorganic acid salt selected from the group consisting of acetate, mesylate, sulfate, citrate, oxalate, hydrochloride, dihydrochloride, isothionate, lactate, and laurate.

11. The method of claim 1 wherein the mammal is a human.

12. A method for treating a solid tumor, colorectal cancer, bladder cancer, gastric cancer, esophageal cancer, head and neck cancer, CNS cancer, malignant glioma, glioblastoma, hepatocellular cancers, thyroid cancer, lung cancer, non-small cell cancer, small cell lung cancer melanoma, myeloma, pancreatic cancer, pancreatic carcinoma, renal cell carcinoma, cervical cancer, urothelial cancer, prostate cancer, castration-resistant prostate cancer, ovarian cancer, breast cancer, triple-negative breast cancer, leukemia, Hodgkins lymphoma, non-Hodgkins lymphoma, B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, diffuse large B-cell lymphoma, Burkitts lymphoma, multiple myeloma, and myelodysplastic syndrome in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of a compound

or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.

13. The method of claim 12 wherein the condition is B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, non-Hodgkins lymphoma, diffuse large B cell lymphoma, Burkitts lymphoma, breast cancer, lung cancer, head and neck cancer, colorectal cancer, prostate cancer, bladder cancer, ovarian cancer, melanoma, hepatocellular cancers, or pancreatic cancer.

14. The method of claim 13 wherein the condition is B-cell lymphoma, breast cancer, lung cancer, colorectal cancer and prostate cancer.

15. The method of claim 12 wherein the pharmaceutically acceptable salt is an organic or inorganic acid salt selected from the group consisting of acetate, mesylate, sulfate, citrate, oxalate, hydrochloride, dihydrochloride, isothionate, lactate, and laurate.

16. The method of claim 15 wherein the pharmaceutically acceptable salt is hydrochloride.

17. The method of claim 12 wherein the mammal is a human.

18. The method of claim 1 wherein the Mnk dependent condition is cancer.

19. The method of claim 18 wherein the condition is a solid tumor, colorectal cancer, bladder cancer, gastric cancer, esophageal cancer, head and neck cancer, CNS cancer, malignant glioma, glioblastoma, hepatocellular cancers, thyroid cancer, lung cancer , non-small cell cancer, small cell lung cancer, melanoma, myeloma, pancreatic cancer pancreatic carcinoma, renal cell carcinoma, cervical cancer, urothelial cancer, prostate cancer, castration-resistant prostate cancer, ovarian cancer, breast cancer, triple-negative breast cancer, leukemia, Hodgkins lymphoma, non-Hodgkins lymphoma, B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, diffuse large B-cell lymphoma, Burkitts lymphoma, multiple myeloma, and myelodysplastic syndrome.

20. The method of claim 19 wherein the condition is B-cell lymphoma, T-cell lymphoma, hairy cell lymphoma, non-Hodgkins lymphoma, diffuse large B cell lymphoma, Burkitts lymphoma, breast cancer, lung cancer, head and neck cancer, colorectal cancer, prostate cancer, bladder cancer, ovarian cancer, melanoma, hepatocellular cancers, or pancreatic cancer.